Patents by Inventor Philip Jonas Sassene

Philip Jonas Sassene has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240067944
    Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
    Type: Application
    Filed: July 7, 2023
    Publication date: February 29, 2024
    Applicant: Novo Nordisk A/S
    Inventors: Andreas Vegge, Daniele Granata, Eva Johansson, Jais Rose Bjelke, Jacob Lund, Philip Jonas Sassene, Per J. Greisen, Thomas Egebjerg, Evelyn De Tavernier, Soren Steffensen, Marie-Ange Buyse, Frantisek Hubalek, Simone Fulle, Mathias Norrman
  • Patent number: 11622996
    Abstract: The invention relates to pharmaceutical compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: April 11, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Simon Bjerregaard, Ulrik Lytt Rahbek, Philip Jonas Sassene, Jorrit Jeroen Water, Andreas Vegge
  • Publication number: 20230087952
    Abstract: The invention relates to pharmaceutical compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
    Type: Application
    Filed: November 16, 2022
    Publication date: March 23, 2023
    Inventors: Simon Bjerregaard, Ulrik Lytt Rahbek, Philip Jonas Sassene, Jorrit Jeroen Water, Andreas Vegge
  • Publication number: 20230000949
    Abstract: The invention relates to pharmaceutical compositions comprising a PCSK9 inhibitor, such as an EGF(A) peptide, and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
    Type: Application
    Filed: November 6, 2020
    Publication date: January 5, 2023
    Inventors: Simon Bjerregaard, Ulrik Lytt Rahbek, Philip Jonas Sassene, Jorrit Jeroen Water, Andreas Vegge, Kaisa Naelapaeae
  • Publication number: 20220395559
    Abstract: The invention relates to pharmaceutical compositions comprising a GLP-1 agonist, an SLGT2 inhibitor, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and a hydrotrope. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
    Type: Application
    Filed: November 6, 2020
    Publication date: December 15, 2022
    Inventors: Kaisa Naelapaeae, Simon Bjerregaard, Ulrik Lytt Rahbek, Philip Jonas Sassene, Jorrit Jeroen Water, Andreas Vegge
  • Publication number: 20210236601
    Abstract: The invention relates to pharmaceutical compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
    Type: Application
    Filed: May 6, 2019
    Publication date: August 5, 2021
    Inventors: Simon Bjerregaard, Ulrik Lytt Rahbek, Philip Jonas Sassene, Jorrit Jeroen Water, Andreas Vegge